I’m 53 years old and 170 pounds lighter than I was a year and a half ago. That’s the number everyone asks about. It’s also the wrong number. The number that actually tells the story is one the bathroom scale never showed me. Over one six-month stretch, the scale said I’d lost 35 pounds. The […]
I’m on Zepbound at a normal dose, the kind a doctor prescribes and a pharmacy fills. A reader sent me a video this week that’s a good way into a question I keep getting asked. In it, the New Zealand GP Brad Stanfield, who runs an evidence-minded health channel, explains that he injects 1.25 milligrams
The CVS Caremark deal just moved a trillion-dollar stock. Here is how Americans actually get Zepbound and Mounjaro across the five channels, who really decides, and what each one costs in 2026.
The American Cancer Society just added a blood test and new stool tests to its colon cancer screening guideline. Why colonoscopy still wins, what each option misses, and how to choose.
I inject myself a few times a week now, GLP-1 and TRT, and barely notice. The needle, not the drug, is the real barrier in modern health, and it is starting to fall.
The first two oral GLP-1 pills are here. A head-to-head on the real weight-loss numbers, daily routine, manufacturing, cost, and who each one actually fits.
Eli Lilly’s VERVE-102 gene-editing therapy cut LDL by 62 percent at the highest dose in Phase 1, with no treatment-related serious adverse events. It edits a single DNA letter in the PCSK9 gene of liver cells. The effect appears permanent. The trade-off is that you cannot undo it.
A new Cell Metabolism paper connects creatine to depression through the gut microbiome. The effect is real, but it shows up only in clinically diagnosed depressed patients who are already on antidepressants. The dose-creep crowd is about to ignore that distinction.
People on tirzepatide ask if brenipatide is the upgrade. People reading about brenipatide ask how it compares to the drug everyone is already on. Same class. Very different jobs. A head-to-head comparison.
Huberman talks about it, Bryan Johnson takes it, Goop sells it, Walgreens stocks it. After months of hearing the NAD+ pitch repeated, I still could not tell whether it was a breakthrough or snake oil. Two new human studies gave me the clearest answer I have read.
